CompletedNot Applicable

High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant

Guadeloupe, Martinique20 participantsStarted 2013-10-31

Plain-language summary

Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI). For patients younger than 65 years old, an allogeneic donor is searching out. Patients included at relapse and with lymphoma clinico-biological subtype also receive chemotherapy (CT). Responses are assessed during ZPI+/-CT and eligible patients (depending on age, comorbidities and response criteria) receive allogeneic transplant. Patient follow-up is planned for 3 years old

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient \>18 years old and ≤ 75 years old, with ATLL-HR who signed informed consent. Exclusion Criteria: * Pregnant or nursing women are not eligible; neither are women of childbearing potential unless using effective contraception as determined by the patient's physician.

What they're measuring

Number of patients with relapse

Timeframe: Up to 3 year

Trial details

NCT IDNCT01941680

SponsorUniversity Hospital Center of Martinique

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-02

View on ClinicalTrials.gov More T-cell Lymphoma trials